Abstract:Antiangiogenesis therapy has become a hot field in cancer research. Blood vessels of tumor carry specific markers that are usually related to angiogenesis. Study of these heterogeneous molecules in different tumor vessels may be beneficial for promoting antiangiogenic therapy. In this study, we established an in vitro co-culture model of human umbilical vein endothelial cells (HUVECs) and gastric adenocarcinoma cell line SGC7901, screened the peptides binding specifically to the HUVECs co-cultured with gastric cancer cells (Co-HUVECs) using phage display peptides library, and studied the affinity of these peptides to gastric cancer vascular endothelial cells. After four rounds of panning, there was an obvious enrichment for the phages specifically binding to the Co-HUVECs, and the output/input ratio of Co-HUVECs increased about 590-fold (from 0.95×10−7 to 561.25×10−7). Five phage clones (M6, M3, M9, IN12, IN11), which could strongly bind to Co-HUVECs instead of wild-type HUVECs, were characterized by ELISA. In vitro cellular binding assay showed that phage IN11 preferably bound to Co-HUVECs rather than control HUVECs, and the number of the phage IN11 recovered from Co-HUVECs was 5.7- and 16.9-folds, respectively, as much as those from control HUVECs and GES cells. Immunocytochemical and immunohistochemical staining confirmed that phage IN11 could specifically bind to Co-HUVECs as well as vascular endothelial cells in gastric cancer tissue sections. Competitive and inhibitory assay revealed the synthetic peptide GEBP11 (CTKNSYLMC) displayed on phage IN11 could competitively inhibit binding of the phage IN11 to Co-HUVECs. Immunofluorescence microscopy showed that the fluorescence-labeled peptide GEBP11 was located at the membrane and perinuclear cytoplasm of Co-HUVECs. Meanwhile, GEBP11 was found to be able to target the gastric cancer vascular endothelial cells. Therefore, GEBP11 may be a potential candidate for targeted drug delivery in antivascular therapy and diagnosis of gastric cancer.

Research priorities on safety of complementary feeding.

Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library

Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library

Specific Ligands for Classical Swine Fever Virus Screened from Landscape Phage Display Library.

A Study on Screening and Antitumor Effect of CD55-specific Ligand Peptide in Cervical Cancer Cells.

Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients.

Selection and identification of a specific peptide binding to ovarian cancer cells from a phage-displayed peptide library

[Screening of Breast Cancer Antigen from a Phage Display Random Peptide Library].

Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular Carcinoma

Identification of a peptide binding to cancer antigen Kita‐kyushu lung cancer antigen 1 from a phage‐display library

Screening of micromolecule polypeptide specific for bladder carcinoma cell T24

Specific coalescent peptides binding with CD59 on HeLa cells screened by phage peptide library

Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers

Screening and identification of a CD44v6 specific peptide using improved phage display for gastric cancer targeting

Screening Tumor-Targeting Bacteriophage Particles by Pre-Clearing Phage Display

Microarray Based Screening of Peptide Nano Probes for HER2 Positive Tumor.

Screening and Identification of Vascular-Endothelial-cell-specific Binding Peptide in Gastric Cancer

A CD44 specific peptide developed by phage display for targeting gastric cancer

Simultaneous Analysis of Cellular Glycoproteome and Phosphoproteome in Cervical Carcinoma by One-Pot Specific Enrichment

Detection of breast cancer-related antigens through cDNA phage-displayed protein microarray.

The further characterization of the peptide specifically binding to gastric cancer